Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
ID: ALA1774892
Max Phase: Preclinical
Molecular Formula: C24H19FO3S
Molecular Weight: 406.48
Molecule Type: Small molecule
Associated Items:
ID: ALA1774892
Max Phase: Preclinical
Molecular Formula: C24H19FO3S
Molecular Weight: 406.48
Molecule Type: Small molecule
Associated Items:
Canonical SMILES: Cc1cc(F)cc(C)c1COc1ccc2c(-c3ccsc3)cc(C(=O)O)cc2c1
Standard InChI: InChI=1S/C24H19FO3S/c1-14-7-19(25)8-15(2)23(14)12-28-20-3-4-21-17(10-20)9-18(24(26)27)11-22(21)16-5-6-29-13-16/h3-11,13H,12H2,1-2H3,(H,26,27)
Standard InChI Key: BZTYQKZVXFALHW-UHFFFAOYSA-N
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Natural Product: No | Oral: No | Chemical Probe: No | Parenteral: No |
Molecule Type: Small molecule | Topical: No | First In Class: No | Black Box: No |
Chirality: No | Availability: No | Prodrug: No |
MESH ID | MESH Heading | EFO IDs | EFO Terms | Max Phase for Indication | References |
---|
Mechanism of Action | Action Type | target ID | Target Name | Target Type | Target Organism | Binding Site Name | References |
---|
Molecular Weight: 406.48 | Molecular Weight (Monoisotopic): 406.1039 | AlogP: 6.60 | #Rotatable Bonds: 5 |
Polar Surface Area: 46.53 | Molecular Species: ACID | HBA: 3 | HBD: 1 |
#RO5 Violations: 1 | HBA (Lipinski): 3 | HBD (Lipinski): 1 | #RO5 Violations (Lipinski): 1 |
CX Acidic pKa: 3.91 | CX Basic pKa: | CX LogP: 6.78 | CX LogD: 3.58 |
Aromatic Rings: 4 | Heavy Atoms: 29 | QED Weighted: 0.41 | Np Likeness Score: -1.08 |
1. Gauthier JY, Belley M, Deschênes D, Fournier JF, Gagné S, Gareau Y, Hamel M, Hénault M, Hyjazie H, Kargman S, Lavallée G, Levesque JF, Li L, Mamane Y, Mancini J, Morin N, Mulrooney E, Robichaud J, Thérien M, Tranmer G, Wang Z, Wu J, Black WC.. (2011) The identification of 4,7-disubstituted naphthoic acid derivatives as UDP-competitive antagonists of P2Y14., 21 (10): [PMID:21507640] [10.1016/j.bmcl.2011.03.081] |
2. (2010) Substituted 2-naphthoic acids as antagonists of gpr105 activity, |
3. Lu R, Zhang Z, Jiang C.. (2019) Recent progress on the discovery of P2Y14 receptor antagonists., 175 [PMID:31071548] [10.1016/j.ejmech.2019.04.068] |
4. Conroy S, Kindon N, Kellam B, Stocks MJ.. (2016) Drug-like Antagonists of P2Y Receptors-From Lead Identification to Drug Development., 59 (22): [PMID:27413802] [10.1021/acs.jmedchem.5b01972] |
Source(2):